Marques Cindy, Cacoub Patrice
"Service de médecine interne et immunologie clinique, Centre de référence des maladies auto-immunes et systémiques rares, Centre de référence des maladies auto-inflammatoires, groupe hospitalier La Pitié-Salpêtrière, AP-HP, Paris, France.Sorbonne Universités, UPMC université de Paris-6, UMR 7211, et département inflammation-immunopathologie-biothérapie (DHU i2B) ; Inserm, UMR S 959 ; CNRS, FRE3632, Paris, France".
Rev Prat. 2021 Jan;71(1):79-83.
"Pericarditis Acute pericarditis is a common disease, most often idiopathic or viral. This is usually a mild condition but recurrences are frequent. The predominant pathophysiological hypothesis is that of underlying dysimmune disorders, involving an inflammatory response of the innate immune system typical of "autoinflammatory diseases", mainly mediated by interleukin-1 [IL-1] with activation of inflammasome; and an adaptive immune system response, typical of «autoimmune diseases», primarily mediated by autoantibodies and autoreactive T cells. The clinical picture associates fever, chest pain, changes in the electrocardiogram and possible pericardial effusion. Treatment is based on the combination of aspirin/nonsteroidal anti-inflammatory drugs and colchicine for several weeks. In refractory pericarditis, low dose corticosteroid therapy and / or immunosuppressive agents have been proposed with limited efficacy. Growing evidency suggest a place for IL-1 receptor antagonists in the treatment of recurrent pericarditis. Many studies have shown the effectiveness of anakinra with a good safety profile. Other IL-1 receptor antagonists have shown promising results (canakinumab, rilonacept). Further evaluation in larger prospective clinical trials is needed to confirm the long-term efficacy and safety of anti-IL1."
心包炎 急性心包炎是一种常见疾病,最常见的病因是特发性或病毒性。该病通常病情较轻,但复发频繁。主要的病理生理假说是存在潜在的免疫失调,涉及先天免疫系统的炎症反应,这是“自身炎症性疾病”的典型特征,主要由白细胞介素-1(IL-1)介导,伴有炎性小体激活;以及适应性免疫系统反应,这是“自身免疫性疾病”的典型特征,主要由自身抗体和自身反应性T细胞介导。临床表现包括发热、胸痛、心电图改变以及可能出现的心包积液。治疗基于阿司匹林/非甾体类抗炎药与秋水仙碱联合使用数周。对于难治性心包炎,已提出使用低剂量皮质类固醇疗法和/或免疫抑制剂,但疗效有限。越来越多的证据表明IL-1受体拮抗剂在复发性心包炎治疗中具有一席之地。许多研究表明阿那白滞素有效且安全性良好。其他IL-1受体拮抗剂也显示出有前景的结果(卡那单抗、利洛纳塞)。需要在更大规模的前瞻性临床试验中进行进一步评估,以确认抗IL-1的长期疗效和安全性。